Thymic Involution

The thymus is the organ responsible for T-cell maturation — the adaptive immune cells that fight infections, cancer, and autoimmunity. It begins shrinking (involuting) after puberty and is largely replaced by fat tissue by age 60-70. This means dramatically fewer new T-cells, a skewed immune repertoire, weaker responses to novel pathogens, and impaired immune surveillance against cancer. Thymosin Alpha-1 directly compensates by enhancing T-cell maturation, dendritic cell antigen presentation, and NK cell activity. It is the only peptide in this class approved as a therapeutic in 35+ countries (marketed as Zadaxin), giving it the strongest regulatory validation of any compound in the Midas Protocol.

The Midas Approach

The Midas Longevity Protocol doesn't address thymic involution in isolation — it targets this pathway alongside 9 other aging mechanisms simultaneously. This multi-pathway approach reflects the scientific consensus that aging is not a single process but a network of interconnected pathways (Lopez-Otin et al., Cell 2023, "Hallmarks of Aging").

Learn more: 12 Hallmarks of Aging & How Midas Maps to Each